HGD抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A549 and HepG2 cell lysates, Primary antibody: P10504(HGD Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P10504(HGD Antibody) at dilution 1/90. (Original magnification: ×200)    

  
  

**Background of HGD Antibodies**

Homogentisate 1.2-dioxygenase (HGD) is a key enzyme in the tyrosine degradation pathway, catalyzing the conversion of homogentisate to maleylacetoacetate. Mutations in the *HGD* gene lead to alkaptonuria (AKU), a rare autosomal recessive disorder characterized by the accumulation of homogentisic acid (HGA). This results in ochronosis (bluish-black pigmentation of connective tissues), joint degeneration, and cardiovascular complications.

HGD antibodies are immunological tools developed to detect and quantify HGD protein expression, aiding in the study of AKU pathogenesis. These antibodies are crucial for immunohistochemistry, Western blotting, or ELISA-based assays to assess HGD levels in tissues or cell models, helping correlate enzyme deficiency with disease severity. Research using HGD antibodies has also advanced understanding of HGD's structural biology and its role in metabolic dysregulation.

Additionally, HGD antibodies hold potential in therapeutic development, such as monitoring enzyme replacement strategies or gene therapy efficacy in preclinical studies. Their specificity enables precise tracking of HGD expression in experimental models, offering insights into corrective approaches for AKU. Overall, HGD antibodies serve as vital reagents in both diagnostic research and translational studies targeting this inherited metabolic disorder.